Multiple Intervention and AUdit in Renal Diseases to Optimize Care (MAURO)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00566033|
Recruitment Status : Completed
First Posted : November 30, 2007
Last Update Posted : January 31, 2012
Test whether the intensive intervention improves renal and cardiovascular outcomes in patients with chronic renal insufficiency.
Test whether a multi-method intensive intervention including clinical Audit improves adherence to a series of quality indicators relevant to hypertension control, proteinuria, treatment of dyslipidemia, anemia, calcium and phosphate alterations in patients with chronic renal insufficiency.
|Condition or disease||Intervention/treatment||Phase|
|Renal Insufficiency||Behavioral: Audit-driven intervention||Phase 4|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||788 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Single (Care Provider)|
|Official Title:||Multiple Intervention and AUdit in Renal Diseases to Optimize Care: the MAURO Study.|
|Study Start Date :||January 2006|
|Actual Primary Completion Date :||August 2011|
|Actual Study Completion Date :||August 2011|
Behavioral: Audit-driven intervention
Patients included in this arm will undergo to the multi-method quality improvement intervention (intensive intervention) that adds practice visits, telephone and e-mail contacts (for quality improvement facilitation) and audits to the approach of periodic guideline dissemination and feedback on demand used in the less intensive intervention.
No Intervention: 2
Patients in this arm (arm 2) will undergo to standard care.
- A composite renal and cardiovascular (CV) end point, i.e. >30% decrease in the GFR, dialysis, transplantation, death or CV event. [ Time Frame: 3 years ]
- The primary renal unit-level outcome is the percentage of performance targets achieved. The primary patient-level outcome is the percentage of patients for whom the recommended process measures occurs. [ Time Frame: 3 years ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00566033
|Nephrology Units participating to the MAURO study in the|
|Calabrian, Sicily, Puglia and Sardenia Regions, Italy|
|Study Director:||Carmine Zoccali, Prof.||CNR-IBIM & Nephrology Unit of Reggio Calabria|